AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.

According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion, ranking as the world’s fourth-largest pharmaceutical company and marking one of the largest mergers and acquisitions in the history of the industry. Sources familiar with the matter revealed that the two companies have held multiple rounds of discussions, and the deal is expected to close soon, though there remains a possibility of delays or a breakdown in negotiations. The potential merger will face antitrust scrutiny from regulators in both countries, as well as concerns from British politicians that AstraZeneca might relocate its registered headquarters to the United States.